Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - Priority Announcement: Antimicrobial Resistance

McGill University

$100,000.00

Host and Viral Determinants of HCV RNA accumulation

EF 2019-20

Résumé
Hepatitis C virus (HCV) infection is a global health problem that affects 71 million people worldwide, including over 250,000 Canadians. HCV-infected individuals typically develop a persistent infection that leads to chronic hepatitis, cirrhosis, steatosis and liver cancer. Currently, there is no vaccine available and although effective antiviral treatments exist, cost and treatment accessibility remain barriers to HCV elimination. To establish an infection, HCV commanders many different factors in our cells. In healthy cells, small molecules, called microRNAs, restrict how much our genes are expressed. HCV co-opts a liver-specific microRNA and uses it to amplify itself. Clinical trials using inhibitors of the microRNA, revealed that preventing the virus from accessing this microRNA may be an effective treatment option. We have preliminary evidence that suggests that HCV uses this microRNA to promote viral protein production and genome stability. The focus of this research is to investigate how HCV uses the microRNA to its own benefit and to identify other human factors that the virus uses to amplify itself in the liver. We will also investigate the mechanisms of resistance-associated variants isolated from patients who underwent miR-122 inhibitor therapy. This research will provide us with insight into mechanisms of microRNA-mediated enhancement of viral replication and may reveal novel antiviral targets. Moreover, as more microRNA-targeted therapies enter the clinic, this work will help to reveal mechanisms of drug resistance that could be applicable more broadly to microRNA-based therapies.
Programme
Project Grant - Priority Announcement: Antimicrobial Resistance
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
415098
Name
Sagan Selena M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
Host and Viral Determinants of HCV RNA accumulation
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Antimicrobial Resistance
Keyworddelim
Apex; Hepatitis C Virus; Mir-122; Protein-Rna Interactions; Replication; Riboswitch; Rna Stability; Rna Structure; Rna-Rna Interactions; Translation
Abstract
Hepatitis C virus (HCV) infection is a global health problem that affects 71 million people worldwide, including over 250,000 Canadians. HCV-infected individuals typically develop a persistent infection that leads to chronic hepatitis, cirrhosis, steatosis and liver cancer. Currently, there is no vaccine available and although effective antiviral treatments exist, cost and treatment accessibility remain barriers to HCV elimination. To establish an infection, HCV commanders many different factors in our cells. In healthy cells, small molecules, called microRNAs, restrict how much our genes are expressed. HCV co-opts a liver-specific microRNA and uses it to amplify itself. Clinical trials using inhibitors of the microRNA, revealed that preventing the virus from accessing this microRNA may be an effective treatment option. We have preliminary evidence that suggests that HCV uses this microRNA to promote viral protein production and genome stability. The focus of this research is to investigate how HCV uses the microRNA to its own benefit and to identify other human factors that the virus uses to amplify itself in the liver. We will also investigate the mechanisms of resistance-associated variants isolated from patients who underwent miR-122 inhibitor therapy. This research will provide us with insight into mechanisms of microRNA-mediated enhancement of viral replication and may reveal novel antiviral targets. Moreover, as more microRNA-targeted therapies enter the clinic, this work will help to reveal mechanisms of drug resistance that could be applicable more broadly to microRNA-based therapies.
Competitiondate
201909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sagan, Selena M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~